Tiger’s Strategic Summary
ZB knows that implants are becoming commodities with an inevitable race to the bottom. ZB also knows that joints are moving to ASCs.
By acquiring iovera°, ZB isn't just buying a piece of hardware; it is weaponizing a clinically proven, non-opioid pain technology to capture the lucrative ASC market.
ZB is using the newly enacted NOPAIN Act as a financial tailwind to transform itself from a simple implant supplier into a full-service partner in surgical throughput and patient recovery.
Full Deal Details
On June 30, 2026, Pacira BioSciences (NASDAQ: PCRX) announced it had entered into an agreement to divest its iovera° cryoneurolysis business to Zimmer Biomet (NYSE: ZBH).
The transaction, valued at up to $140 million, represents a clean strategic pivot for both companies amid shifting medtech dynamics, regulatory tailwinds, and focused corporate priorities.
Zimmer Biomet will pay $70 million upfront in cash (subject to customary adjustments) plus up to an additional $70 million in revenue-based milestone payments through December 31, 2031. The deal is expected to close in the third quarter of 2026, supported by a standard transition services agreement (TSA...
